Skip to content

Study · Animal study (in vivo) · mouse · 2020

24 results

Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice.

Arlt H, Mullarkey T, Hu D, Baron R, Ominsky MS, Mitlak B, Lanske B, Besschetnova T

Bone reports26 Jun 2020Cited by 25 (Europe PMC)

PMID32637467 (opens in a new tab)PMCIDPMC7330158 (opens in a new tab)DOI10.1016/j.bonr.2020.100291 (opens in a new tab)PepBankPUB-32637467
Read at sourcePubMedAsk about this study
Jump to 24 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study24

22 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide at the lower dose did not change calvarial resorption cavities versus vehicle.

    In plain wordsIn mice, lower-dose abaloparatide did not change skull bone resorption cavities compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeCalvarial resorption cavities
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Terminal bone histomorphometry data indicated that calvarial resorption cavities were similar in both abaloparatide groups versus vehicle controls, whereas the teriparatide group had more calvarial resorption cavities compared with the vehicle or abaloparatide 40 μg/kg groups.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide at the higher dose did not change calvarial resorption cavities versus vehicle.

    In plain wordsIn mice, higher-dose abaloparatide did not change skull bone resorption cavities compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeCalvarial resorption cavities
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Terminal bone histomorphometry data indicated that calvarial resorption cavities were similar in both abaloparatide groups versus vehicle controls, whereas the teriparatide group had more calvarial resorption cavities compared with the vehicle or abaloparatide 40 μg/kg groups.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide increased calvarial resorption cavities versus vehicle.

    In plain wordsIn mice, teriparatide increased skull bone resorption cavities compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCalvarial resorption cavities
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Terminal bone histomorphometry data indicated that calvarial resorption cavities were similar in both abaloparatide groups versus vehicle controls, whereas the teriparatide group had more calvarial resorption cavities compared with the vehicle or abaloparatide 40 μg/kg groups.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide increased calvarial resorption cavities versus higher-dose abaloparatide.

    In plain wordsIn mice, teriparatide increased skull bone resorption cavities compared with higher-dose abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCalvarial resorption cavities
    Study

    mousen: not reported in source

    female mice
    Comparator
    abaloparatide 40 μg/kg
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Terminal bone histomorphometry data indicated that calvarial resorption cavities were similar in both abaloparatide groups versus vehicle controls, whereas the teriparatide group had more calvarial resorption cavities compared with the vehicle or abaloparatide 40 μg/kg groups.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, higher-dose abaloparatide lowered serum CTX versus vehicle.

    In plain wordsIn mice, higher-dose abaloparatide lowered the bone resorption marker CTX compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseSerum CTX
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    The bone resorption marker serum CTX was significantly lower in the abaloparatide 40 μg/kg group and similar in the other two active treatment groups compared with vehicle controls.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, lower-dose abaloparatide did not change serum CTX versus vehicle.

    In plain wordsIn mice, lower-dose abaloparatide did not change CTX compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeSerum CTX
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    The bone resorption marker serum CTX was significantly lower in the abaloparatide 40 μg/kg group and similar in the other two active treatment groups compared with vehicle controls.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide did not change serum CTX versus vehicle.

    In plain wordsIn mice, teriparatide did not change CTX compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeSerum CTX
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    The bone resorption marker serum CTX was significantly lower in the abaloparatide 40 μg/kg group and similar in the other two active treatment groups compared with vehicle controls.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, lower-dose abaloparatide increased L5 trabecular bone formation rate versus vehicle.

    In plain wordsIn mice, lower-dose abaloparatide increased vertebral bone formation compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseL5 trabecular bone formation rate
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both peptides increased trabecular bone formation rate (BFR) in L5 and proximal tibia versus vehicle, and L5 BFR was higher with abaloparatide 40 μg/kg versus teriparatide.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, higher-dose abaloparatide increased L5 trabecular bone formation rate versus vehicle.

    In plain wordsIn mice, higher-dose abaloparatide increased vertebral bone formation compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseL5 trabecular bone formation rate
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both peptides increased trabecular bone formation rate (BFR) in L5 and proximal tibia versus vehicle, and L5 BFR was higher with abaloparatide 40 μg/kg versus teriparatide.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide increased L5 trabecular bone formation rate versus vehicle.

    In plain wordsIn mice, teriparatide increased vertebral bone formation compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseL5 trabecular bone formation rate
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both peptides increased trabecular bone formation rate (BFR) in L5 and proximal tibia versus vehicle, and L5 BFR was higher with abaloparatide 40 μg/kg versus teriparatide.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, lower-dose abaloparatide increased proximal tibial trabecular bone formation rate versus vehicle.

    In plain wordsIn mice, lower-dose abaloparatide increased tibial bone formation compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseProximal tibial trabecular bone formation rate
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both peptides increased trabecular bone formation rate (BFR) in L5 and proximal tibia versus vehicle, and L5 BFR was higher with abaloparatide 40 μg/kg versus teriparatide.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, higher-dose abaloparatide increased proximal tibial trabecular bone formation rate versus vehicle.

    In plain wordsIn mice, higher-dose abaloparatide increased tibial bone formation compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseProximal tibial trabecular bone formation rate
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both peptides increased trabecular bone formation rate (BFR) in L5 and proximal tibia versus vehicle, and L5 BFR was higher with abaloparatide 40 μg/kg versus teriparatide.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide increased proximal tibial trabecular bone formation rate versus vehicle.

    In plain wordsIn mice, teriparatide increased tibial bone formation compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseProximal tibial trabecular bone formation rate
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both peptides increased trabecular bone formation rate (BFR) in L5 and proximal tibia versus vehicle, and L5 BFR was higher with abaloparatide 40 μg/kg versus teriparatide.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, higher-dose abaloparatide increased L5 trabecular bone formation rate versus teriparatide.

    In plain wordsIn mice, higher-dose abaloparatide increased vertebral bone formation compared with teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseL5 trabecular bone formation rate
    Study

    mousen: not reported in source

    female mice
    Comparator
    teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both peptides increased trabecular bone formation rate (BFR) in L5 and proximal tibia versus vehicle, and L5 BFR was higher with abaloparatide 40 μg/kg versus teriparatide.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, higher-dose abaloparatide increased tibial periosteal bone formation rate versus vehicle.

    In plain wordsIn mice, higher-dose abaloparatide increased outer tibial bone formation compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTibial periosteal bone formation rate
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    At the tibial diaphysis, periosteal BFR was higher with abaloparatide 40 μg/kg versus vehicle or teriparatide, and endocortical BFR was higher with teriparatide but not with abaloparatide 10 or 40 μg/kg versus vehicle.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, higher-dose abaloparatide increased tibial periosteal bone formation rate versus teriparatide.

    In plain wordsIn mice, higher-dose abaloparatide increased outer tibial bone formation compared with teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTibial periosteal bone formation rate
    Study

    mousen: not reported in source

    female mice
    Comparator
    teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    At the tibial diaphysis, periosteal BFR was higher with abaloparatide 40 μg/kg versus vehicle or teriparatide, and endocortical BFR was higher with teriparatide but not with abaloparatide 10 or 40 μg/kg versus vehicle.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  17. 17AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide increased tibial endocortical bone formation rate versus vehicle.

    In plain wordsIn mice, teriparatide increased inner cortical bone formation compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial endocortical bone formation rate
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    At the tibial diaphysis, periosteal BFR was higher with abaloparatide 40 μg/kg versus vehicle or teriparatide, and endocortical BFR was higher with teriparatide but not with abaloparatide 10 or 40 μg/kg versus vehicle.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  18. 18AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, lower-dose abaloparatide did not increase tibial endocortical bone formation rate versus vehicle.

    In plain wordsIn mice, lower-dose abaloparatide did not increase inner cortical bone formation compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeTibial endocortical bone formation rate
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    At the tibial diaphysis, periosteal BFR was higher with abaloparatide 40 μg/kg versus vehicle or teriparatide, and endocortical BFR was higher with teriparatide but not with abaloparatide 10 or 40 μg/kg versus vehicle.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  19. 19AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, higher-dose abaloparatide did not increase tibial endocortical bone formation rate versus vehicle.

    In plain wordsIn mice, higher-dose abaloparatide did not increase inner cortical bone formation compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeTibial endocortical bone formation rate
    Study

    mousen: not reported in source

    female mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    At the tibial diaphysis, periosteal BFR was higher with abaloparatide 40 μg/kg versus vehicle or teriparatide, and endocortical BFR was higher with teriparatide but not with abaloparatide 10 or 40 μg/kg versus vehicle.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  20. 20AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, higher-dose abaloparatide produced fewer calvarial resorption cavities than teriparatide.

    In plain wordsIn mice, higher-dose abaloparatide produced fewer skull bone resorption cavities than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseCalvarial resorption cavities versus teriparatide
    Study

    mousen: not reported in source

    female mice
    Comparator
    teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Terminal bone histomorphometry data indicated that calvarial resorption cavities were similar in both abaloparatide groups versus vehicle controls, whereas the teriparatide group had more calvarial resorption cavities compared with the vehicle or abaloparatide 40 μg/kg groups.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  21. 21AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide produced lower L5 trabecular bone formation rate than higher-dose abaloparatide.

    In plain wordsIn mice, teriparatide produced lower vertebral bone formation than higher-dose abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseL5 trabecular bone formation rate versus abaloparatide
    Study

    mousen: not reported in source

    female mice
    Comparator
    abaloparatide 40 μg/kg
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both peptides increased trabecular bone formation rate (BFR) in L5 and proximal tibia versus vehicle, and L5 BFR was higher with abaloparatide 40 μg/kg versus teriparatide.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.
  22. 22AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide produced lower tibial periosteal bone formation rate than higher-dose abaloparatide.

    In plain wordsIn mice, teriparatide produced lower outer tibial bone formation than higher-dose abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTibial periosteal bone formation rate versus abaloparatide
    Study

    mousen: not reported in source

    female mice
    Comparator
    abaloparatide 40 μg/kg
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 μg/kg · supra-calvarial subcutaneous injection · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    At the tibial diaphysis, periosteal BFR was higher with abaloparatide 40 μg/kg versus vehicle or teriparatide, and endocortical BFR was higher with teriparatide but not with abaloparatide 10 or 40 μg/kg versus vehicle.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 23AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome

    In female mice, the brief study found few structural or microarchitectural bone differences across treatment groups including abaloparatide.

    In plain wordsIn mice, the brief study found few bone structure differences across groups including abaloparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    MixedStructural and microarchitectural bone parameters
    Study

    mousen: not reported in source

    female mice
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Few differences in structural or microarchitectural bone parameters were observed with this brief duration of treatment.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 24AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In female mice, the brief study found few structural or microarchitectural bone differences across treatment groups including teriparatide.

    In plain wordsIn mice, the brief study found few bone structure differences across groups including teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedStructural and microarchitectural bone parameters
    Study

    mousen: not reported in source

    female mice
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Few differences in structural or microarchitectural bone parameters were observed with this brief duration of treatment.
    2 context sentences
    Summary · context
    This study in 8-week-old female mice compared bone resorption and formation responses to these agents delivered at the same 10 μg/kg dose, and a 40 μg/kg abaloparatide dose was also included to reflect its 4-fold higher approved clinical dose.
    Summary · context
    Peptides or vehicle were administered by daily supra-calvarial subcutaneous injection for 12 days, and local (calvarial) and systemic (L5 vertebral and tibial) responses were evaluated by histomorphometry.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.